title: Intravitreal anti-vascular endothelial growth factor versus observation in acute central serous chorioretinopathy: one-year results.
abstract: OBJECTIVE
  To evaluate the efficacy of anti-vascular endothelial growth factor (VEGF) compared with observation for treating acute central serous chorioretinopathy (CSC).
  
  
  METHODS
  A retrospective study of 36 patients with acute CSC, including 21 patients treated with anti-VEGF (anti-VEGF group) and 15 patients with observation (observation group). Patients in the anti-VEGF group received a single dose of bevacizumab or ranibizumab at baseline. Best-corrected visual acuity (BCVA), central foveal thickness (CFT) and resolution of subretinal fluid (SRF) on optical coherence tomography (OCT) were assessed. The integrity of the foveal inner segment/outer segment (IS/OS) line at 12 months was also analyzed.
  
  
  RESULTS
  Resolution of SRF was achieved in 20 of 21 eyes in the anti-VEGF group and in 12 of 15 eyes in the observation group (p = 0.151). Mean BCVA and CFT were not different between the two groups at 12 months (p > 0.05). The amount of change in BCVA, however, differed significantly between the groups (p = 0.044). Final OCT more frequently detected the foveal IS/OS line in the anti-VEGF group than in the observation group (p = 0.012).
  
  
  CONCLUSIONS
  In terms of BCVA, anti-VEGF and observation only had similar therapeutic effects in acute CSC patients. In some patients, however, the rapid resolution of SRF by anti-VEGF might reduce the risk of photoreceptor degeneration and improve long-term visual acuity.
authors.affiliation: Department of Ophthalmology, Kangwon National University School of Medicine, Chuncheon, Korea.
authors.forename: Sang-Uk
authors.initials: SU
authors.lastname: Park
authors.affiliation: Department of Ophthalmology, Kangwon National University School of Medicine, Chuncheon, Korea.
authors.forename: Seung-Jun
authors.initials: SJ
authors.lastname: Lee
authors.affiliation: Department of Ophthalmology, Kangwon National University School of Medicine, Chuncheon, Korea.
authors.forename: Moosang
authors.initials: M
authors.lastname: Kim
mesh_terms: D000208:Acute Disease; D000328:Adult; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000627:therapeutic use; D056833:Central Serous Chorioretinopathy / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D008875:Middle Aged; D019370:Observation; D000069579:Ranibizumab / Q000627:therapeutic use; D055211:Retinal Photoreceptor Cell Inner Segment / Q000473:pathology; D055214:Retinal Photoreceptor Cell Outer Segment / Q000473:pathology; D012189:Retrospective Studies; D058471:Subretinal Fluid / Q000187:drug effects; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity
chemical_list: D020533:Angiogenesis Inhibitors; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D000069579:Ranibizumab
keywords: Anti-vascular endothelial growth factor; Central serous chorioretinopathy; One year